#Obesity medicine
Chronic weight management as a clinical specialty.
GLP-1 Drugs and Skin Cancer Risk
A new Dermatologic Surgery paper links semaglutide and tirzepatide to lower skin cancer rates in patients with obesity, but the abstract isn't public yet.
Testing Tirzepatide After Gastric Bypass
A Vanderbilt pilot trial called GRABS is testing tirzepatide in patients whose obesity persists after gastric bypass surgery.
Incretin malnutrition review explained
A new review of tirzepatide, semaglutide and related trials raises nutrition questions without proving common clinical malnutrition.
What Medicare's GLP-1 bridge may cost
CMS has disclosed Medicare's $50 GLP-1 copay and a manufacturer net price, but not a total taxpayer cost estimate.
Mwyngil's non-GLP-1 obesity approach
Mwyngil is pursuing GPR75 and NLRP3 pathways for obesity. The targets are interesting, but the program remains preclinical.
How to read an oral GLP-1 script tracker
A new tracker follows oral Wegovy and Foundayo prescriptions. Here is what script growth can show, and what it cannot.
Does tirzepatide cut carpal tunnel risk?
A 2026 cohort study links tirzepatide to fewer carpal tunnel diagnoses than other weight drugs. That is an association, not a treatment effect.
Why GLP-1 prescriptions go unfilled
About 40% of GLP-1 orders are never dispensed. Here is what the fill-rate evidence on semaglutide and tirzepatide shows, and what it cannot show.
Finding at-risk MASH without a liver biopsy
With semaglutide approved for MASH, finding the right patients is the bottleneck, and a new study says a liver stiffness scan can do it without a biopsy.
GLP-1 drugs, PCOS, and trying to conceive
GLP-1 medicines such as semaglutide are not approved to treat PCOS, and current labels require stopping the drug before a planned pregnancy.
STEP 12: semaglutide in Chinese adults
STEP 12 tested semaglutide 2.4 mg in Chinese adults at a BMI of 24 to under 30, a band the earlier STEP obesity trials never enrolled.
Tirzepatide at 6 months: who stays on it
A US claims study of 22,512 tirzepatide starters found 68% still on the drug at six months. Here is what that number does and does not tell you.